Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 14;14(1):67-76.
doi: 10.2174/1573403X14666180123165542.

Hypertriglyceridemia - Common Causes, Prevention and Treatment Strategies

Katarzyna Rygiel  1
Affiliations
Review

Hypertriglyceridemia - Common Causes, Prevention and Treatment Strategies

Katarzyna Rygiel. Curr Cardiol Rev. .

Abstract

Background: Prevention and treatment of dyslipidemias represent the key issues of Cardiovascular Disease (CVD) prophylaxis. Consequently, the effective management of different types of lipid disorders, including hypertriglyceridemia, should be a priority for the healthcare practitioners (e.g.: cardiology and endocrinology specialists, primary care physicians, dietitians, and pharmacists), who provide medical care, as well as for the patients, who receive this care, and need to be directly engaged in it, in order to improve their outcomes. The aim of this review is to facilitate the translation of current trends in hypertriglyceridemia management into a daily practice. The article focuses on the common causes and consequences of hypertriglyceridemia, and discusses diagnostic evaluation and therapeutic options for patients with high Triglyceride (TG) levels and CVD risk.

Conclusion: This review presents the main practice-related strategies, based on the current guidelines for the management of dyslipidemias and CVD risk, according to the European Society of Cardiology (ESC), the European Atherosclerosis Society (EAS), and the American College of Cardiology (ACC)/American Heart Association (AHA), including both non-pharmacological, and pharmacological approaches. It also addresses the beneficial impact of pharmaceutical Care (PC) interventions on clinical outcomes of patients with lipid disorders and CVD risk (in light of Randomized Controlled Trials (RCT) data), and underlines the importance of close cooperation between physicians and pharmacists, who manage such patients.

Keywords: Cardiovascular Diseases (CVD); Pharmaceutical Care (PC); Triglyceride (TG) levels.; dyslipidemia; hypertriglyceridemia; patient management.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Remnant cholesterol and atherosclerosis.
See this image and copyright information in PMC

References

    1. Reiner Z, Catapano AL, De Backer G, et al. European Association for Cardiovascular Prevention Rehabilitation1. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2011;32:1769–818. - PubMed
    1. Miller M., Stone N.J., Ballantyne C., et al. The american heart association clinical lipidology, thrombosis, and prevention committee of the council on nutrition, physical activity and metabolism, council on arteriosclerosis, thrombosis and vascular biology, council on cardiovascular nursing, and council on the kidney in cardiovascular disease. Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association. Circulation. 2011;123:2292–2333. - PubMed
    1. Stone N.J., Robinson J.G., Lichtenstein A.H., et al. The American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25) Suppl. 2:S1–S45. - PubMed
    1. Ray K.K., Kastelein J.J., Boekholdt S.M., et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: The good the bad and the uncertain: A comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur. Heart J. 2014;35:960–968. - PubMed
    1. Jellinger P.S., Smith D.A., Mehta A.E., et al. American Association of Clinical Endocrinologists’ guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr. Pract. 2012;18(Suppl. 1):1–78. - PubMed

MeSH terms

Substances